PT - JOURNAL ARTICLE AU - Blasiak, Agata AU - Lim, Jhin Jieh AU - Seah, Shirley Gek Kheng AU - Kee, Theodore AU - Remus, Alexandria AU - Chye, De Hoe AU - Wong, Pui San AU - Hooi, Lissa AU - Truong, Anh T.L. AU - Le, Nguyen AU - Chan, Conrad E.Z. AU - Desai, Rishi AU - Ding, Xianting AU - Hanson, Brendon J. AU - Chow, Edward Kai-Hua AU - Ho, Dean TI - IDentif.AI: Artificial Intelligence Pinpoints Remdesivir in Combination with Ritonavir and Lopinavir as an Optimal Regimen Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) AID - 10.1101/2020.05.04.20088104 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.04.20088104 4099 - http://medrxiv.org/content/early/2020/05/08/2020.05.04.20088104.short 4100 - http://medrxiv.org/content/early/2020/05/08/2020.05.04.20088104.full AB - The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) has led to the rapid initiation of urgently needed clinical trials of repurposed drug combinations and monotherapies. These regimens were primarily relying on mechanism-of-action based selection of drugs, many of which have yielded positive in vitro but largely negative clinical outcomes. To overcome this challenge, we report the use of IDentif.AI, a platform that rapidly optimizes infectious disease (ID) combination therapy design using artificial intelligence (AI). In this study, IDentif.AI was implemented on a 12-drug candidate therapy search set representing over 530,000 possible drug combinations. IDentif.AI demonstrated that the optimal combination therapy against SARS-CoV-2 was comprised of remdesivir, ritonavir, and lopinavir, which mediated a 6.5-fold improvement in efficacy over remdesivir alone. Additionally, IDentif.AI showed hydroxychloroquine and azithromycin to be relatively ineffective. The identification of a clinically actionable optimal drug combination was completed within two weeks, with a 3-order of magnitude reduction in the number of tests typically needed. IDentif.AI analysis was also able to independently confirm clinical trial outcomes to date without requiring any data from these trials. The robustness of the IDentif.AI platform suggests that it may be applicable towards rapid development of optimal drug regimens to address current and future outbreaks.Competing Interest StatementA.B., T.K., L.H. X.D., E.K.C., and D.H. are co-inventors or previously filed pending patents on artificial intelligence-based therapy development.Clinical TrialThis study was done on patient-derived live virus from a local patient following ethics approval (reference 10). Note: The extraordinarily large drug/dose space interrogated using IDentif.AI has enabled its previous use as a direct clinical decision support platform for multiple human studies and indications. In addition, we have cited all relevant registry numbers based on confirmatory studies using IDentif.AI.Funding StatementD.H. gratefully acknowledges support from the Office of the President, Office of the Senior Deputy President and Provost, and Office of the Deputy President for Research and Technology at the National University of Singapore. D.H. also gratefully acknowledges the Ministry of Education Tier 1 FRC Grant. D.H. and E.K.C. gratefully acknowledge the National Research Foundation Singapore under its AI Singapore Programme (Award Number: AISG-GC-2019-002), and Singapore Ministry of Health’s National Medical Research Council under its Open Fund-Large Collaborative Grant ("OF-LCG")(MOH-OFLCG18May-0028). E.K.C. is supported by the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence Initiative (Cancer Science Institute of Singapore RCE Main Grant), Ministry of Education Academic Research Fund (MOE AcRF Tier 2 [MOE2019-T2-1-115]), Singapore Ministry of Health’s National Medical Research Council under its Open Fund-Large Collaborative Grant ("OF-LCG")(MOH-OFLCG18May-0023 and MOH-OFLCG18May-0028) and National Research Foundation Competitive Proton Research Programme (NRF-CRP-2017-05). X.D. acknowledges support from National Key Research and Development Program of China (2017ZX10203205) and National Science Foundation of China (81871448). S.G.K.S., D.H.C., P.S.W., C.E.Z.C. and B.J.H gratefully acknowledge funding support from Future Systems and Technology Directorate, Singapore Ministry of Defence. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data has been included in the supplementary section. The authors can be contacted if additional information is needed.